Dongkoo Bio&Pharma, top sales company in dermatology, working on IPO
Dongkoo Bio&Pharma(CEO Yong-Joon Cho) has selected NH Investment & Securities as its stock firm and gotten on an IPO process by filing a screening to the Korea Exchange on the 25th. The amount of stocks expected to be issued is 2,069,120 stocks.
Dongkoo Bio&Pharma, a pharmaceutical company found...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
